18/06/2024  22:10:00 Var. +0.10 Volume Denaro00:11:36 Lettera00:11:36 Capitalizzazione di mercato Dividend Y. Rapporto P/E
64.96USD +0.15% 181,271
Fatturato: 6.1 mill.
59.50Quantità in denaro: 100 67.94Quantità in lettera: 100 3.24 bill.USD - -

Descrizione business

Prestige Consumer Healthcare, Inc. markets and distributes brand name over-the-counter healthcare products throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® eye care products, DenTek® and The Doctor's® oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® sore throat treatments, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Efferdent® denture care products, Luden's® throat drops, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia.
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Ron Lombardi
Consiglio di amministrazione
Christine Sacco, Adel Mekhail, Jeff Thompson, Jeff Zerillo, Mary Beth Fritz, William P'Pool
Consiglio di sorveglianza
Ron Lombardi, Christopher J. Coughlin, Dawn M. Zier, Dr. Celeste A. Clark, Dr. Gary E. Costley, James M. Jenness, John E. Byom, Natale S. Ricciardi, Sheila A. Hopkins
 

Dati aziendali

Name: Prestige Consumer Healthcare, Inc.
Indirizzo: 660 White Plains Road,Tarrytown, New York 10591, USA
Telefono: +1-914-524-6800
Fax: -
E-mail: Irinquiries@prestigebrands.com
Internet: www.prestigebrandsinc.com/
Industria: Consumer Goods
Settore: Cosmetics
Sub settore: Cosmetics
Fine dell'anno finanziario: 31/03
Flottante libero: 69.88%
Data dell'IPO: -

Rapporti con gli investitori

Name: Phil Terpolilli
IR telefono: +1-914-524-6819
IR Fax: -
IR e-mail: -

Principali azionisti

Freefloat
 
69.88%
BlackRock, Inc.
 
12.50%
The Vanguard Group
 
10.72%
Dimensional Fund Advisors LP
 
6.90%